**CERTIFICATE OF ANALYSIS**

**CERTIFICATE No:** CAN/2015-16/433

|  |  |  |  |
| --- | --- | --- | --- |
| **PRODUCT** | TENOFOVIR DISOPROXIL FUMARATE/ LAMIVUDINE/ EFAVIRENZ TABLETS 300 mg/300 mg/ 600 mg | | REF. NO: NDQB201601712 |
| **DATE RECEIVED:** 26.01.2016 | **LABEL CLAIM:** | Each film coated tablet contains: Tenofovir disoproxil fumarate 300 mg, Lamivudine USP 300 mg and Efavirenz USP 600 mg. | |
| **BATCH NO.:** 3029684 | **PRESENTATION:** | Off white coloured, caplet-shaped, biconvex faced tablets, embossed 'M 152' on one face and plain on the other, packed in a white plastic multi-dose container carrying 30 tablets in a unit box. | |
| **MGF. DATE:** Aug. 2014 | **MANUFACTURER:** | MYLAN Laboratories Limited. | |
| **EXP. DATE:**  Jul. 2016 | **ADDRESS:** | F - 4 & F - 12, MIDC, Malegaon, Sinnar, Nashik - 422 113, Maharashtra, INDIA. | |
| **CLIENT REF NO:** | **CLIENT:** | Kenya Medical Supplies Authority, P.O. Box 47715 - 00100, Nairobi, KENYA | |
|  | **TEST(S) REQUESTED:** | Uniformity of Weight, Identification, Dissolution, Assay | |

**RESULTS**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **TEST** | **METHOD** | **COMPEDIA** | **SPECIFICATION** | **DETERMINED** | **REMARKS** |
| **Uniformity of Weight** | Weight | BP 2016 Vol. V App XII C | NMT 2 tablets deviate by more than 5% from mean tablet weight | None Deviates | **COMPLIES** |
| **Identification** | HPLC | Adopted In-House Method | RT of the Component Peaks in the assay sample preparation correspond to those in the assay standard preparation | Super-imposable peaks at RT 4.2; 16.4; 25.3 -/+ 10% min. present in both the assay sample and standard preparations | **COMPLIES** |
| **Dissolution** | HPLC | Adopted In-House Method | No tablet less than 80.0% (n=6) | Efavirenz 94.3% (RSD=2.7%, n=6) | **COMPLIES:COMPLIES:COMPLIES** |
| **Dissolution** | HPLC | Adopted In-House Method | No tablet less than 80.0% (n=6) | Lamivudine 94.5% (RSD=0.9%, n=6) | **COMPLIES:COMPLIES:COMPLIES** |
| **Dissolution** | HPLC | Adopted In-House Method | No tablet less than 80.0% (n=6) | Tenofovir disoproxil fumarate 90.3% (RSD=4.8%, n=6) | **COMPLIES:COMPLIES:COMPLIES** |
| **Assay** | HPLC | Adopted In-House Method | 90.0 - 110.0% | Efavirenz 96.9% (RSD=0.5%, n=9) | **COMPLIES:COMPLIES:COMPLIES** |
| **Assay** | HPLC | Adopted In-House Method | 90.0 - 110.0% | Lamivudine 97.0% (RSD=0.4%, n=6) | **COMPLIES:COMPLIES:COMPLIES** |
| **Assay** | HPLC | Adopted In-House Method | 90.0 - 110.0% | Tenofovir disoproxil fumarate 97.2% (RSD=1.4%, n=9) | **COMPLIES:COMPLIES:COMPLIES** |

**CONCLUSION:** The product complies with the specifications for the tests performed.

|  |  |  |  |
| --- | --- | --- | --- |
| ANALYST: | DR. L. WANGARI |  | DATE:01-03-2016 |
| ANALYST: | DR. E. TANUI |  | DATE:04-03-2016 |
| ANALYST: | ERNEST MBAE |  | DATE:03-10-2016 |
| DIRECTOR: | HEZEKIAH CHEPKWONY |  | DATE:03-15-2016 |